Advisory Board

Advisory Board

Azar Delpassand, RN, BSN

Founder, Board Member of RadioMedix

President and Founder of 

Excel Diagnostics & Nuclear Oncology Center

  • + 20 years of experience as a serial entrepreneur in the healthcare industry 
  • Co-founder of three additional healthcare start-ups 
  • Infinity Infusion Care and Infinity Care, Inc. (named in 1997 as one of the 100 fastest growing companies)                     
  • President and CEO of both Infinity Infusion Care and Infinity Care, Inc. 

Dr.Ferey Faridian

Member of Board of Directors and senior advisor to the CEO

Ferey helps CEOs, founders and investors align to deliver their company’s mission of growth all the way to exit. He has helped numerous founder/owners, CEOs and investors as adviser or Board member to meet challenges of growth, transitions, transactions and successful sale of the business. He leverages the Newport Partner network, his focus on strategy and finance and his career experience as serial CEO, PE principal, VC partner, ibanker, corporate strategist to Fortune 100 clients in aerospace, biotech and medical devices, wireless/TMT, energy and industrials. PhD EE (UCL), MBA (Cambridge).

Amanda Walker, MD

Assistant Professor of Radiation Oncology 

and Radiation Molecular Sciences at Johns Hopkins 

Amanda Walker is an Assistant Professor of Radiation Oncology and Radiation Molecular Sciences at Johns Hopkins and practices in the Greater Washington Area. She previously served as a medical officer in the Office of Hematology Oncology Products and was the Associate Director (Acting) of Radiation Oncology in the FDA's Oncology Center of Excellence. At the FDA, Dr. Walker advised Industry and Academia with respect to oncology products, clinical trial design, and regulatory pathways to accelerate public access to novel drugs and devices. She has organized a number of workshops and symposia including the 2018 Clinical Development of Drug-Radiotherapy Combinations Workshop co-sponsored by the FDA, AACR, and ASTRO as well as outreach activities pertaining to novel oncology products, including radiopharmaceuticals. Dr. Walker graduated summa cum laude from Indiana University and then earned her medical degree from Tufts University. She completed a preliminary year in Internal Medicine at the University of Chicago, followed by her residency training in radiation oncology at the Johns Hopkins Hospital. In addition to her time at the FDA she previously served as Adjunct Investigator in the Radiation Oncology Branch at the National Cancer Institute and also spent time in a private practice in New England.    

Hossein Jadvar, MD, PhD, MPH, MBA

Tenured Associate Professor of Radiology 

University of Southern California (USC) in Los Angeles

Dr. Jadvar is a physician-scientist with an academic appointment as tenured Associate Professor of Radiology at the University of Southern California (USC) in Los Angeles. He is also a member of the USC Norris Comprehensive Cancer Center, and Associate Professor of Biomedical Engineering in the USC Viterbi School of Engineering. He received his PhD in bioengineering (1988), from the University of Michigan, Ann Arbor, the MD degree from the University of Chicago Pritzker School of Medicine (1993), Master’s in Public Health (MPH) degree from Harvard University (2005), and the Executive Master’s in Business Administration (MBA) from USC Marshall School of Business (2007). He was an intern in internal medicine at the University of California San Francisco (UCSF) during 1993-94, a diagnostic radiology and nuclear medicine resident at Stanford University, during 1994-98, and a clinical fellow in positron emission tomography (PET) with the Harvard Medical School Joint Program in Nuclear Medicine, during 1998-99. He is past president and fellow of both the American College of Nuclear Medicine (ACNM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). He has extensive documented experience in clinical, research, education, administration, radiation safety, outreach, and advocacy for diagnostic and therapeutic nuclear medicine. His research interests include applications of PET in clinical outcome research and in translational molecular imaging research with particular current interest in prostate cancer, theranostics, and targeted radionuclide therapy.